Although low-energy shock wave (SW) is adopted to treat ischemic diseases because of its pro-angiogenic properties, the underlying mechanism remains unclear. This study is aimed at testing whether SW-induced angiogenesis may be through endothelial vascular endothelial growth factor receptor 2 (VEGFR2) signaling and trafficking. Phosphorylation of VEGFR2-Akt-eNOS axis and production of nitric oxide (NO) were determined in human umbilical vein endothelial cells (HUVECs) treated with SW. Carotid artery in ob/ob mice was treated with SW before evaluation with sprouting assay. Critical limb ischemia was induced in ob/ob mice to evaluate blood flow recovery post-SW treatment. Tube formation and migration assays were also performed with/without SW treatment in the presence/absence of SU5416 (VEGFR2 kinase inhibitor) and siRNA-driven silencing of VEGFR2. Chloroquine was used for disrupting endosome, and Rab11a controlling slow endocytic recycling was silenced with siRNA in vitro. Following SW treatment, augmented ligand-independent phosphorylation in VEGFR2-Akt-eNOS axis and endogenous NO production, increased cellular migration and tube formation and elevated sprouting of carotid artery and blood flow in ischemic limb in ob/ob mice were noted. Moreover, SU5416 and VEGFR2 silencing both inhibited SW-induced angiogenesis. SW-induced angiogenesis, accompanied by increased VEGFR2 protein expression without transcriptional change, was suppressed by chloroquine and Rab11a silencing. We concluded that SW enhanced angiogenesis via ligand-independent activation of VEGFR2 and further prolonged angiogenesis through endosome-to-plasma membrane recycling in endothelial cells.
or injuries using different animal models, including burn wounds, myocardial infarction and critical limb ischemia (7) (8) (9) (10) (11) . Despite clear demonstration of SW-induced angiogenesis in those studies, the exact mechanisms remain poorly understood.
In the processes of stimulation generated by blood flow-induced shear stress, vascular endothelial growth factor receptor 2 (VEGFR2) acts as a mechanotransducer to transmit activated signal through ligand-independent phosphorylation, thereby leading to vasodilation via endothelial nitric oxide synthase (eNOS) activation (12) and plays a predominate role in VEG-FR2-induced angiogenesis (13) . Similar to laminar shear stress in endothelial cells, SW has been reported to lead to adopted for the treatment of musculoskeletal disorders (1) (2) (3) (4) . Recently, low-energy SW has been shown to be a promising therapeutic option in the treatment of erectile dysfunction (5, 6) . A number of studies have attempted to extend SW application to other diseases
InTRODuCTIOn
Shock wave (SW) therapy is a noninvasive mechanical treatment strategy that has been applied clinically for decades. While high-energy SW is widely used to splinter stones over the urinary tract, low-energy SW is commonly
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Tien-Hung Huang, 1 Cheuk-Kwan Sun, 7 Yi-Ling Chen, 1 Ching-Jen Wang, 3, 4 Tsung-Cheng Yin, 4 Mel S Lee, 4* and Hon-Kan Yip mechanosensory complex formation and Akt/eNOS phosphorylation (14) . On the other hand, VEGFR2 undergoes constitutive endosome-to-plasma membrane recycling in endothelial cells (15) . VEGFR2 recycling accompanies dephosphorylation of VEGFR2 through endosomal vesicles (16) . Thus, balance of VEGFR2 recycling is important for signal in and out. Receptor traffic also has been reported to be affected by external environmental factors including infection, aging and degenerative diseases (17) as well as stimulation by fluid shear stress in renal proximal tubular cells (18) . However, whether SWinduced angiogenesis is associated with VEGFR2 recycling is still unknown. The present study, therefore, tested the hypothesis that low-energy SW treatment may trigger the VEGFR2-Akt-eNOS axis and further prolong angiogenesis through endocytic VEGFR2 recycling in endothelial cells.
MaTERIaLS anD METHODS

Ethics
All animal experimental proce 
Shock Wave Treatment
Focused SW with adjustable levels between 0.10 to 0.15 mJ/mm 2 was produced from HMT Evotron Shock Wave Therapy Device (HMT High Medical Technologies). Before SW treatment, HUVECs were pre-washed once by PBS and filled with PBS in a culture dish without any bubble. Probe of the SW-producing device was applied vertically on the top of the culture dish with ultrasound gel ( Figure 1A ). Culture dishes were purchased from TPP (surface area size 60.1 cm 2 ).
Cell Culture HUVEC cells were purchased from Bioresource Collection and Research Center (BCRC). Culture medium (endothelial cell medium, ECM) was purchased from SciencCell. HUVEC cells between passage 4 to 6 were used in this study and were grown at 37°C under 5% CO 2 in 0.1% gelatin pre-coated culture dish. Transfection of siRNAs (50 nmol/L) into HUVECs was accomplished with TransIT-X2 dynamic delivery system (Mirus) in complete medium for 3 d, according to the manufacturer's recommendation. Addition of SU5416 was performed prior to tube formation assay. Cycloheximide (CHX, 10 μg/mL) and chloroquine (CHQ, 5 μmol/L and 20 μmol/L) were added into the medium 2 h post-SW treatment. For another 26 h incubation, treated HUVECs were subjected to tube formation assay.
nitric Oxide Detection
Intracellular nitric oxide (NO) production was determined using specific cell permeable fluorescent probe 4-amino-5-methylamino-2',7'-difluorofluorescein diacetate (DAF-FM DA; Molecular Probes). After SW treatment, 5 μmol/L of DAF-FM diacetate was added into HUVECs in serum-and growth factor-free M199 basal medium, defined as basal medium (BM), and incubated at 37°C for 40 min. Green fluorescent derivate was converted in the presence of NO and was counterstained with Hoechst 33342. The fluorescence signals were analyzed using fluorescence microscopy (Olympus Bx51).
PKH26 and PKH67 Staining
PKH26 (MINI26) and PKH67 (MINI67) were all purchased from Sigma-Aldrich. For general cell membrane labeling, control and SW-treated HUVECs were stained with PKH26 (red fluorescence dye) and PKH67 (green fluorescence dye), respectively. Cells were labeled according to the manufacturer's protocol. After membrane labeling, both cells were mixed together with equal numbers, and were subjected to tube formation assay. The fluorescence signals were captured using fluorescence microscopy (Olympus IX51).
Cell Proliferation assay
After SW treatment, HUVECs were plated onto a 96-well plate. Rate of cell proliferation in 4 consecutive days was determined by incubation with 0.5 mg/ mL MTT (AMRESCO) for 4 h and the precipitated formazan was dissolved in DMSO. The supernatant was assessed at a wavelength of 540 nm.
Wound-Healing Migration assay and Transwell Migration assay
For the wound-healing migration assay, HUVECs were plated onto culture insert (iBidi GmbH). After full confluence of culture cells, the insert was removed and replaced by serum-and growth factor-free M199 basal medium (BM) for migration assay. After 16 h incubation, images of cell migration were retrieved using an inverted phase contrast microscope (Olympus IX51), and were quantitated by WimScratch (Wimasis Image Analysis). For the transwell migration assay, HUVECs were plated on 6-well transwells with 8-μm pore-size insert (Falcon) precoated with 0.1% gelatin. , 200 impulses at a frequency of 2 Hz on both sides of the neck and were allowed to recover for 2 d post treatment. For ex vivo angiogenesis assay, SWtreated carotid arteries were separated and cut into small pieces of approximately 1 mm × 1 mm, and further rinsed HUVECs were seeded on the bottom of the culture dish, and were cultured with M199 medium (1% FBS) at 37°C with 5% CO 2 . After 16 h, nonmigrated cells were removed from the upside of insert, and migrated cells in the underside were fixed by methanol and further counted by the hematoxylin staining.
Sprouting assay
Adult male leptin-deficient mice (ob/ob), a well-established model of distance were quantitated by WimSprout (Wimasis Image Analysis).
Mouse Critical Limb Ischemia Model and Measurement of Blood Flow with Laser Doppler Flowmetry
Adult male ob/ob mice were randomly divided into two groups (control group and SW group) and anesthetized preoperatively with 3% isoflurane prior to CLI induction (n = 4 for each group). Under sterile conditions, the left femoral artery, small arterioles and circumferential femoral artery were exposed and ligated over their proximal and distal portions before removal. Shock wave at an energy of 0.12 mJ/mm 2 , 200 impulses with frequency of 2 Hz. was administered at d 1 and 7 after induction of critical limb ischemia (CLI). Fourteen days post-CLI, the mice were placed in a supine position and the blood flow detected in both inguinal areas by a laser Doppler flowmetry (moorLDLS, Moor Co.). The ratio of flow in left leg (ischemic) to that of right leg (normal) was calculated.
Rna Extraction and Real-Time RT-qPCR Total RNA was extracted using Trizol reagent (Invitrogen), following the protocol of the manufacturer. Reverse transcription was performed by Transcriptor First Strand cDNA Synthesis Kit (Roche). Expression of VEGFR2 was determined by using Quantifast SYBR Green PCR kit (Qiagen) with the forward primer of 5′-GTGACCAACATGGAGTCGTG -3′ and the reverse primer of 5′-TGCTTCA-CAGAAGACCATGC -3′, and normalized by GAPDH expression with the forward primer of 5′-GACAGTCAG-CCGCATCTTCTT-3′ and the reverse primer of 5′-CCAATACGACCAAATC-CGTTGAC-3′. Triplicate assays were performed for each sample on Step OnePlus machine (ABI).
Western Blot
Protein was extracted from cultured cells by using cell scraper and RIPA buffer with protease and phosphatase inhibitor. Approximate amounts of protein were subjected to SDS-PAGE and transferred to membranes. The membranes were incubated with the primary antibody, including actin (1:1000, MAB1501, Millipore), VEGFR2, phospho-VEGFR2 (Tyr 1175) (1:500, 3770, Cell Signaling), Akt (1:1000, 9272, Cell Signaling), phospho-Akt (Ser 473) (1:1000, 9271, Cell Signaling), eNOS (1:1000, 9572, Cell Signaling) and phospho-eNOS (1:500, 9571, Cell Signaling). Horseradish peroxidase (HPR)-conjugated secondary antibody was used for binding the primary antibody. Immunoreactive bands were visualized by enhanced chemiluminescence (ECL, Amersham Biosciences) and protein bands were quantified using ImageJ software.
Tube Formation assay
HUVEC cells were transfected transiently with scramble siRNA or VEGFR2 siRNA or Rab11a. Three days posttransfection, transfected HUVEC cells were seeded on Matrigel-coated μ-slide (iBidi GmbH) with serum-and growth factor-free M199 basal medium (BM) for tube formation assay. Treatment of SU5416 (S8442, Sigma-Aldrich), or chloroquine (CHQ) (C6628, Sigma-Aldrich) was performed prior to tube formation assay. After 6 h incubation, images of network generated from tube formation were retrieved using an inverted phase-contrast microscope (Olympus IX51), and were quantitated by WimTube (Wimasis image analysis). Parameters, including total tube lengths, branch points and loop numbers, were quantitated and transformed into percentage relative to control.
Collection of Conditioned Medium and Enzyme-Linked Immunosorbent assay (ELISa) for VEgFa
Conditioned medium was collected from HUVECs with or without SW treatment after tube formation assay (50 μL/each well in μ-slide) and further centrifuged at 290g for 5 min to eliminate unnecessary cells. Conditioned medium was applied in two assays.
One was a tube formation assay for the determination of conditioned medium-induced angiogenesis in HUVECs, while the other was quantification of secreted VEGFA by ELISA (eBioscience, BMS277) in conditioned medium according to the manufacturer's recommendation.
Statistical analysis
GraphPad Prism software (ver. 6) (GraphPad Software) was used for statistical analyses and data plotting. Results shown are mean with SD. Significance of difference among different groups was analyzed by unpaired Student t test and post-test for a linear trend. A probability value < 0.05 was considered statistically significant.
RESuLTS
Low-Energy Shock Wave Treatment Displayed Harmless Effects on HuVECs
To determine whether HUVECs displayed cellular apoptosis in response to SW treatment, we applied three different low-energy levels (0.10, 0.12 and 0.15 mJ/mm 2 ) to determine the apoptotic and DNA-damaged protein expression by Western blot post-SW treatment ( Figure 1B Figure 2D) . The results showed co-constructure from normal and SW-treated HUVECs. Therefore, we demonstrated that SW-treated HUVECs expressed normal tube formation function compatible with that of neighboring endothelial cells in BM.
Characteristic Difference between normal and SW-Treated HuVECs
To examine whether the property of endothelial cells was altered by SW treatment, we performed wound healing, transwell migration and cellular proliferation assays with control and SW-treated HUVECs. In both wound healing and transwell migration assay,
SW-Induced angiogenesis Revealed a Dose-Dependent Increase
A few tube structures were founded in serum-and growth factor-free M199 basal medium (BM) as compared with that of complete medium. To evaluate whether SW conducted angiogenesis with a dose-dependent increase, different conditions (below 0.12 mJ/mm 2 ,
200 impulses with frequency of 2 Hz) in BM for SW delivery were applied in HUVECs and further examined by tube formation assay (Figure 2A-B) . By comparing control to SW-treated HUVECs with increasing energy and pulses, there were significant progressive increases in angiogenesis, quantitated by the parameters of tube length (P for trend = 0.0092), branch point (P for trend = 0.0189) and loop number (P for trend = 0.0287) ( Figure 2C Figure 1C) . Addition of recombinant VEGF protein was used as positive control. In serum-and growth factor-free M199 basal medium (BM), SW evoked strong VEGFR2, Akt and eNOS phosphorylation at 30 min and further reduced at 90 min as compared with the phosphorylation status in the control. To examine the production of NO, DAF-FM diacetate was used as an indicator to assess nitric oxide (NO) production post-SW treatment ( Figure 1D ). The number of nitric oxide-converted fluorescent cells in the SW group was significantly higher than that in the control group (P = 0.0025) ( Figure 1E ). These results indicated that ligand-independent activation of VEGFR2-Akt-eNOS axis, which plays a predominant role in angiogenesis, was revealed in HUVECs post SW treatment. suggested that SW-induced angiogenesis was not caused by secreted factors including VEGFA. VEGFR2 has been known to be a critical signaling receptor involved in angiogenesis. To clarify the role of VEGFR2 in SW-induced angiogenesis, VEGFR2-inhibitor and VEGFR2-specific siRNAs were applied in HUVECs. Treatment of SU5416 (a selective inhibitor of tyrosine kinase activity of VEGFR2) significantly inhibited SW-induced angiogenesis (Figure 6B-C) (n = 7, all parameters showed P < 0.0005). Furthermore, knockdown of VEGFR2 protein expression was conducted by three different siRNAs, No.1 and No.2 were used for VEGFR2 knockdown ( Figure 6D ). Inhibition of SW-induced angiogenesis was also demonstrated in HUVECs transfected with the two siRNAs ( Figure 6E -F) (n = 6, all parameters showed P < 0.05). Therefore, we assumed that VEGFR2 protein expression plays a critical role in SW-induced angiogenesis.
Recycling of Endocytic VEgFR2
Increased post-SW Treatment Interestingly, we found that VEGFR2 protein expression showed a significant elevation 28 h post-SW treatment ( Figure 7A ) (n = 4, P = 0.0032) without VEGFR2 mRNA increase ( Figure 7B ). We wonder whether an increase of VEGFR2 protein expression was determined by endosome-to-plasma membrane recycling. To address the role of SW in endosome recycling specifically, a mediator of recycling endosome, Rab11a, which regulated late endocytic recycling (19) , was silenced by specific siRNAs. Knockdown of Rab11a protein expression was conducted by three different siRNAs (No.1, No.2, and No.3) and the latter two siRNAs were used for Rab11a inhibition ( Figure 7C ). Angiogenesis was found to be inhibited in HUVECs transfected with those two siRNAs ( Figure 7D-E) .
To locate the elevated VEGFR2 expression in HUVECs, cell lysates were fractionized into three different compartments (membrane, cytosol and nucleus proteins). Although VEGFR2 protein expression (P = 0.0191, P = 0.0077) ( Figure 4A-B) . In the critical limb ischemia model ( Figure 4C-D) , ob/ob mice with SW treatment (n = 4) also showed higher recovered blood flow than those in the control (n = 4) (P = 0.0384).
SW-Induced angiogenesis Mediated by VEgFR2
To clarify the mechanism of SW-induced angiogenesis, we compared the effects of control-conditioned medium (CM) to those of SW-treated CM in tube formation assay, but there was no significant difference in angiogenesis ( Figure 5A-B) . Furthermore, quantification of vascular endothelial growth factor A (VEGFA) under both conditions also displayed no significant difference ( Figure 5C ). The results, therefore, SW-treated HUVECs showed significantly higher migration than control (P = 0.0031 and 0.0002) ( Figure 3A-B) . In cellular proliferation assay, there were no significance differences during the first 2 d, but a higher proliferation rate was displayed in SW-treated HUVECs at d 3 (P = 0.0007) ( Figure 3C ).
angiogenesis Enhanced by SW Ex Vivo and In Vivo
To examine the capacity of angiogenesis ex vivo and in vivo, we performed carotid artery sprouting assay and Matrigel plug assay to quantitate the difference in angiogenesis with and without SW treatment. In carotid sprouting assay, mice with SW treatment exhibited significantly higher sprout areas and sprout distances than those in the control in endothelial cells. We successfully established an optimal SW setting for the induction of angiogenesis in vitro, ex vivo and in vivo. The prolonged SW-induced angiogenesis was found to be attributable to an increased number of VEGFR2 from endosome-plasma-membrane recycling regardless of protein synthesis. Importantly, this was an advantageous method to characterize an endocytic VEGFR2 recycling pathway in endothelial cells in response to SW treatment.
Diabetic patients exhibit impaired angiogenesis through inhibition of nitric oxide (NO) synthesis and display damaged vessel wall structure via formation of advanced glycation end products (AGEs) (22) . Diabetic foot, which is one of the common vascular complications of diabetes, compartment was increased dramatically post-CHQ treatment, possibly as a result of endosome disruption ( Figure 8B ). Furthermore, SW-induced angiogenesis as reflected in tube formation was found to be inhibited by CHQ treatment ( Figure  8C-D) . By contrast, treatments with CHX alone and CHX + CHQ did not disrupt tube formation in the condition of complete medium (Figure 8E-F) . Taken together, the results indicated that part of SW-induced angiogenesis may be caused by VEGFR2 endosome recycling.
DISCuSSIOn
The major findings of this study are that SW not only enhanced angiogenesis but also prolonged its duration through VEGFR2 activation following recycling did not change after the first 4 h of SW administration in the membrane protein compartment, it was increased 28 h post-SW treatment ( Figure 8A ), implying that SW-induced VEGFR2 recycling may sustain more than 1 d.
To examine whether endosome abnormalities affect SW-induced angiogenesis, HUVECs were treated with cycloheximide (CHX) and chloroquine (CHQ) post-SW for tube formation assay. Cycloheximide (CHX) was applied for inhibition of protein synthesis. On the other hand, chloroquine (CHQ) has been reported to induce an abnormal endocytic pathway including blocking of endosome acidification as well as swelling of the endosome (20, 21) . Thus, VEGFR2 protein expression in cytosol VEGFA signaling through VEGFR2 is the major pathway that activates angiogenesis through migration, proliferation and sprouting in endothelial cells (26) . In this study, augmentation of migration is noted in SW-treated HUVECs without the addition of exogenous VEGFA, implying that the role of VEGFA in angiogenesis may be replaced by SW through ligand-independent VEGFR2 activation in endothelial cells. We identified that SW-induced tube formation in the condition of serum-and growth factor-free M199 basal medium (BM) was very similar to that of tube formation undergoing the condition of complete medium. This hypothesis was further supported by the findings that SW-induced tube formation was significantly suppressed through either the inhibition of VEGFR2 kinase activity or the silencing of VEGFR2 protein expression in the absence of VEGFA. Intriguingly, a previous study has exhibited that mechanical stress also creates an increase of intracellular calcium in endothelial cells (27) . Additionally, except for Akt phosphorylation, an increase in the release of intracellular calcium has been shown to enhance eNOS phosphorylation (28) . In this way, we proposed that the level of intracellular calcium might be altered by SW treatment, which in turn, further augmented eNOS phosphorylation at 30 min. This hypothesis could explain why the VEGF-induced level of eNOS phosphorylation was lower than that induced by SW treatment at 30 min.
Many studies have demonstrated the effectiveness of SW treatment as a noninvasive therapeutic strategy against ischemic disease in animal models (9, 29, 30) and human heart diseases (31, 32) . Although the condition of SW treatment has not achieved consistence, the mechanism for SW-induced angiogenesis is generally considered to be activated by the phosphorylation of Akt and eNOS in endothelial cells (14) . In the same way, we have demonstrated that SW treatment enhanced angiogenesis in swine myocardial infraction and rat limb ischemia models in our previous studies mice displayed enhanced sprouting in carotid artery and increased recovery of blood flow in critical limb ischemia. Therefore, we demonstrated that the condition for SW treatment adopted for the present study could enhance angiogenesis in vitro, ex vivo and in vivo.
has been known to accompany severe pathological impairments in peripheral arteries and neurons (23) . Recently, SW therapy has been applied in patients with diabetic foot ulcer for improving the rate of wound healing (24, 25) . In this study, we also found that SW treatment in ob/ob the membrane fraction did not increase during the first few hours post-SW treatment. On the other hand, the mechanism of NO-mediated VEGFR2 recycling is still poorly understood.
Our findings demonstrated that VEGFR2 may undergo enhanced been reported to inhibit externalization of tissue transglutaminase (tTG) through attenuation of recycling endosomes in human aortic endothelial cells (33) . We assume that recycling of endocytic VEGFR2 may be repressed by NO production so that VEGFR2 expression in (8, 10) . However, we find that activation of VEGFR2-Akt-eNOS signaling pathway per se is insufficient to explain the increase in VEGFR2 protein expression following SW treatment without mRNA changes. Furthermore, both exogenous and endogenous nitric oxide (NO) have endocytic recycling post-SW treatment. Recycling of membrane receptors is generally believed to be attained through two pathways. While one is the fast pathway that involves the endocytosis of membrane receptors with the formation of early endosome that quickly fuses with cell membrane (within minutes) with the presentation of receptors, again on the cell surface via Rab4a, the other slow recycling pathway (within hours) comprises transformation of early endosome into recycling endosome before receptor presentation on cell membrane. In this picture, Rab11a has been reported to be associated with slow recycling trafficking (19, 34) , the silencing of which has been demonstrated to suppress VEGFA-stimulated migration and proliferation, as well as tube formation in HUVECs (35) . Consistently, we found that silencing of Rab11a also reduced tube formation post-SW treatment without exogenous VEGFA activation, implying that Rab11a-mediated slow recycling pathway is associated with SW treatment. In our vessel sprouting (ex vivo) and limb ischemia (in vivo) models, we also observed that SW-induced angiogenesis was prolonged more than a week. Taken together, we assumed that SW-induced VEGFR2 recycling may be achieved mainly by slow endosomal recycling through Rab11a instead of rapid endosomal recycling via Rab4a (36, 37 ).
In the current study, we also displayed that Na/K ATPase, which acted as a membrane-specific marker, was also increased post-SW treatment. Interestingly, an effect of laminar fluid shear stress has been reported to be similar to low-energy SW treatment (14) , and treatment of laminar fluid shear stress induced a great surface expression of NA/K ATPase on MPT cells by the stimulation of exocytic pathway (38) . Hence, we speculated that expression of Na/K ATPase might also be regulated by SW treatment through endosome recycling, suggesting further investigation is required.
The present study has several limitations. First, this study explored only the angiogenic effect of SW treatment on endothelial cells in vitro. Therefore, the SW effect on adjacent stromal cells is still unclear, so the establishment of an endothelial-stromal cells co-culture model for this issue is necessary. Second, there has not been tangible evidence showing the linkage between nitric oxide production and VEGFR2 recycling post-SW treatment. Third, although the results are promising, the mechanism underlying SW-induced endosome recycling remains to be elucidated.
COnCLuSIOn
The current study demonstrated that VEGFR2 activation and recycling were augmented by SW treatment in endothelial cells, and were associated with enhanced and prolonged angiogenesis. Our findings not only delineated a novel mechanism underlying SW treatment, but also unveil the possibility of novel drug development for the treatment of ischemic diseases through enhancement of VEGFR2 recycling.
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